Crime against Humanity<br/>—Uncovering Two Decades of Corruption in the FDA Regarding DMD Treatment

• 作者: Peter K. Law
• 来源期刊: 再生医学期刊(英文)
• 学科: 医学
• 关键词: FDA CORRUPTION DMD DUCHENNE Muscular DYSTROPHY Exondys 51 MYOBLAST Transfer Therapy Peter K. Law Disqualification
• 年，卷（期）: 2017,（4）
• 页码范围: 35-45
• 页数: 11页
• 分类号: R73

摘要

The world needs to know the facts as to how the FDA “protects” the public health by assuring the safety, effectiveness, and security of human drugs and biological products for human use. Recent uproar has surfaced over the FDA’s approval process on the unproven Duchenne Muscular Dystrophy (DMD) drug, Exondys 51 (Sarepta Therapeutics, Cambridge, MA, USA), but what many people do not know are the unlawful events that occurred nearly two decades ago on a proven and promising treatment for DMD.